Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Haleh Kadkhoda"'
Autor:
Patrick Kugel, Leisha A. Emens, Kinjal Parikh, Ann Carothers, Haleh Kadkhoda, Charlotte Warren
Publikováno v:
Cancer Research. 81:PS9-15
Background:Immunotherapy was first introduced into the treatment of triple negative breast cancer with the approval of nab-paclitaxel + atezolizumab in patients with metastatic PD-L1-positive disease. Continued research sheds light on the utility of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19627b7fb3cd7df6b4a0e21ecad55bfb
https://doi.org/10.1158/1538-7445.sabcs20-ps9-15
https://doi.org/10.1158/1538-7445.sabcs20-ps9-15
Publikováno v:
Gynecologic Oncology. 162:S177
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::844641ba3beb2c673a751e15553181bd
https://doi.org/10.1016/s0090-8258(21)00980-x
https://doi.org/10.1016/s0090-8258(21)00980-x
Autor:
Emily Sherene Van Laar, Donna L. Topping, Saee Dhoble, Kinjal Parikh, Haleh Kadkhoda, Patrick Kugel, Jacob Cohen
Publikováno v:
Journal of Clinical Oncology. 39:492-492
492 Background: Immunotherapy (IO) utility in bladder cancer (UC) has expanded into multiple stages of disease. Employing IO optimally requires mastery of clinical trial data, patient eligibility criteria, and interpretation of biomarkers and determi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42e945893ceb4567ea11729a1a120c53
https://doi.org/10.1200/jco.2021.39.6_suppl.492
https://doi.org/10.1200/jco.2021.39.6_suppl.492
Autor:
Patrick Kugel, Kinjal Parikh, Charlotte Warren, Haleh Kadkhoda, Emily Sherene Van Laar, Katie S. Lucero
Publikováno v:
Journal of Clinical Oncology. 39:479-479
479 Background: Gastrointestinal (GI) cancers are a heterogeneous group of cancers with varying underlying pathophysiology and distinct treatment paradigms. Immunotherapy (IO) is unique in each of the subtypes and biomarkers utility varies. With the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04231cddaa71cd6d54324c705a2300c2
https://doi.org/10.1200/jco.2021.39.3_suppl.479
https://doi.org/10.1200/jco.2021.39.3_suppl.479
Autor:
Haleh Kadkhoda, Charlotte Warren, Ann Carothers, Emily Sherene Van Laar, Katie S. Lucero, Kinjal Parikh, Brian I. Rini
Publikováno v:
Journal of Clinical Oncology. 38:e17076-e17076
e17076 Background: Cytokine therapy was initially the only immunotherapy for patients with advanced renal cell carcinoma (RCC). The advent of targeted therapies ushered in a new area of precision medicine in the treatment paradigm. Recently, immunoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b97bc9b7540751657bad79a3a91af38a
https://doi.org/10.1200/jco.2020.38.15_suppl.e17076
https://doi.org/10.1200/jco.2020.38.15_suppl.e17076
Autor:
Jeffrey S. Weber, Haleh Kadkhoda, Kinjal Parikh, Jacqueline Gearhart, Charlotte Warren, Patti Repetto, Katie S. Lucero
Publikováno v:
Journal of Clinical Oncology. 37:10533-10533
10533 Background: The indications and use of immune checkpoint inhibitors (ICIs) for the treatment of melanoma have grown since the first drug approval in 2011. The expanding evidence base and number of indications challenges clinicians to stay up to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c4150236fdb1346d956248200303256
https://doi.org/10.1200/jco.2019.37.15_suppl.10533
https://doi.org/10.1200/jco.2019.37.15_suppl.10533
Publikováno v:
Journal of Clinical Oncology. 37:e18249-e18249
e18249 Background: The indications and use of immune checkpoint inhibitors (ICIs) in the treatment of advanced and metastatic lung cancer have grown dramatically since the first lung cancer drug approval in 2015. The rapid pace of change can make it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0768de52123b831685c4903bd5db3e0e
https://doi.org/10.1200/jco.2019.37.15_suppl.e18249
https://doi.org/10.1200/jco.2019.37.15_suppl.e18249
Autor:
Jacqueline Gearhart, Jeffrey S. Weber, Charlotte Warren, Haleh Kadkhoda, Patti Repetto, Lori Keys Pender, Katie S. Lucero
Publikováno v:
Journal of Clinical Oncology. 37:e18224-e18224
e18224 Background: Immune checkpoint inhibitors (ICIs) are increasingly used in oncology care and produce a wide variety of immune-related adverse events (irAEs) that differ from toxicities of other systemic therapies. The objective of this study was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d838c77254eca0bb9c567e72bae41712
https://doi.org/10.1200/jco.2019.37.15_suppl.e18224
https://doi.org/10.1200/jco.2019.37.15_suppl.e18224
Publikováno v:
Journal of Clinical Oncology. 36:651-651
651 Background: The objective of this study was to determine the effect of online, case-based, continuing medical education (CME) on the knowledge and competence of oncologists regarding the management of metastatic renal cell cancer (mRCC). Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b110cd18626e99b7a8cb3a0c9b23119
https://doi.org/10.1200/jco.2018.36.6_suppl.651
https://doi.org/10.1200/jco.2018.36.6_suppl.651
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts The treatment of cancer is undergoing a revolution, thanks to new advances in the understanding of the immune system. As part of an ongoing educational curriculum, initial assessment of oncologists' knowledge and practice patterns i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65695913edb5306c5481ff005f82a704
https://doi.org/10.1186/2051-1426-3-s2-p135
https://doi.org/10.1186/2051-1426-3-s2-p135